Calgary, AB – May 9, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences
company with a mission to deliver medicalized ibogaine-centered addiction care, advises of the departure
of two members of its Board of Directors (the “Board”). Dr. Alberto Sola Agullo has decided to resign from
the Board in order to focus his time on his ibogaine based addiction treatment business, Clear Sky Recovery
Cancun SA de CV (“Clear Sky”) which operates in Cancun, Mexico. In conjunction, Robert Turner has
also chosen to resign from the Board, which continues with members Ian Campbell (Chairman), Anthony
Decristofaro, and Nick Karos (CEO).
The Company thanks Dr. Sola and Mr. Turner for their ongoing insight and guidance to date as Board
members. UI also acknowledges and thanks Dr. Sola for his development and completion of the ibogaine
based addiction treatment protocol which was previously acquired by UI under an exclusive global licensing
agreement with Clear Sky, and which the Company will use as part of the foundation for its planned clinical
trial application to Health Canada for the use of ibogaine in the treatment of opioid use disorder.
UI also advises of the expansion of its Advisory Board to include Amanda Zinter. Candice Wilson and
Amanda Zinter the founders of WilsonZinter Enterprises Ltd., who live and work on the unceded territories
of the Haisla Nation and Semiahmoo First Nation, and both work closely with Haisla Nation, Candice as the
Environment Manager and Amanda as a Regulatory Consultant. WilsonZinter was formed to promote
indigenous involvement in project development across Canada. Candice and Amanda have deep expertise
in government, regulatory, social governance, indigenous rights, and promoting partnerships with
businesses that want to demonstrate high levels of social responsibility through their involvement in the
incorporation and promotion of indigenous rights and the necessity of understanding the knowledge the
culture brings to environment and its connection back to oneself.
CEO Nick Karos commented “Like many start-up ventures, the Board of UI has evolved over time, and we
will seek to fill the current vacancies with appropriate new members. Separately, we are pleased to have
Amanda Zinter join our team in an advisory capacity. Her network and expertise will help us advance our
mission with various regulatory bodies and continue to deepen our commitment to potential future
partnerships with First Nations groups.”
The UI Advisory Board was formed in November 2022, and is intended to allow the Company to draw on a
broad range of expertise and experience of its members from various fields, including medical practice,
First Nations leadership, psychedelics research, government relations and grant funding.
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine
through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that
treatment protocol globally through planned future licensing agreements. UI is concurrently developing a
state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre (located near Winnipeg,
Manitoba) that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize
the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT
TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is
frequently characterized by words such as “plans”, “planned”, “expect”, “project”, “intends”, “intended” “will”,
“believe”, “anticipate”, “estimate”, “scheduled”, “potential”, or other similar words, or statements that certain
events or conditions “may”, “should” or “could” occur. The forward-looking statements and information are
based on certain key expectations and assumptions made by UI. Although UI believes that the
expectations and assumptions on which the forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements because UI can give no assurance that
they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve
inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due
to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals
are not obtained. The reader is cautioned that assumptions used in the preparation of such information,
although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers
are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions
as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forwardlooking information contained herein to reflect events or circumstances that occur after the date hereof or
to reflect the occurrence of unanticipated events, except as may be required under applicable securities
For further information:
Investor Relations: Dugan Selkirk, Investor Relations Manager